Scholarlink

<p>Feline panleukopenia virus (FPV), feline calicivirus (FCV), and feline herpesvirus-1 (FHV-1) substantially impact feline health. Field evidence on vaccine-induced population immunity remains limited. We evaluated humoral responses in 4,736 vaccinated domestic cats across 24 provinces in China (July 2024–June 2025), quantifying neutralizing antibody titers to FPV, FCV, and FHV-1 after a trivalent inactivated vaccine (Meowonder™). For cats aged 3 months or older, two primary doses achieved high antibody positivity rates across pathogens; a third dose yielded marginal additional benefit, while boosters-maintained titers. Antibody peaks occurred in late summer and early winter, with a decline beginning in February and a rebound in spring. Maternal-derived antibodies (MDAs) interfered most in kittens &lt; 4 months. A subset with very high FPV titers but sub-threshold FCV/FHV-1 titers had recent environmental FPV based on pet owners’ feedback. The variability of individual immune responsiveness, potentially influenced by feline leukocyte antigen (FLA) polymorphisms, likely contributed to heterogeneous responses. These results support a two-dose primary series for cats aged ≥ 3 months, followed by periodic boosters, emphasizing the importance of vaccine schedules and consideration of genetic and environmental factors for effective disease management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluating triple inactivated vaccine-induced immunity from a large-scale study in feline population

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月10日

查看全文
  • Yanhui Wang,
  • Yuxiu Liu,
  • Peipei Qiao,
  • Hongchao Wu,
  • Caihong Liu,
  • Yihang Yang,
  • Yujiao Cao,
  • Ningning Cui,
  • Lu Wang,
  • Mufei Huang,
  • Xiangfeng Xi,
  • Kegong Tian

摘要

Feline panleukopenia virus (FPV), feline calicivirus (FCV), and feline herpesvirus-1 (FHV-1) substantially impact feline health. Field evidence on vaccine-induced population immunity remains limited. We evaluated humoral responses in 4,736 vaccinated domestic cats across 24 provinces in China (July 2024–June 2025), quantifying neutralizing antibody titers to FPV, FCV, and FHV-1 after a trivalent inactivated vaccine (Meowonder™). For cats aged 3 months or older, two primary doses achieved high antibody positivity rates across pathogens; a third dose yielded marginal additional benefit, while boosters-maintained titers. Antibody peaks occurred in late summer and early winter, with a decline beginning in February and a rebound in spring. Maternal-derived antibodies (MDAs) interfered most in kittens < 4 months. A subset with very high FPV titers but sub-threshold FCV/FHV-1 titers had recent environmental FPV based on pet owners’ feedback. The variability of individual immune responsiveness, potentially influenced by feline leukocyte antigen (FLA) polymorphisms, likely contributed to heterogeneous responses. These results support a two-dose primary series for cats aged ≥ 3 months, followed by periodic boosters, emphasizing the importance of vaccine schedules and consideration of genetic and environmental factors for effective disease management.